Fibroblast growth factor 21 (FGF21) has recently emerged as a promising therapeutic agent for the treatment of obesity and T2D (Kharitonenkov & DiMarchi, 2017). Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.